Catalent Inc (NASDAQ:CTLT) insider John R. Chiminski sold 73,819 shares of the business’s stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $28.62, for a total value of $2,112,699.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Catalent Inc (NASDAQ:CTLT) traded down 0.97% during midday trading on Monday, hitting $28.45. The stock had a trading volume of 307,813 shares. The firm has a market cap of $3.55 billion and a price-to-earnings ratio of 39.57. Catalent Inc has a 1-year low of $20.94 and a 1-year high of $32.24. The firm has a 50-day moving average price of $28.51 and a 200-day moving average price of $26.06.
Catalent (NASDAQ:CTLT) last released its earnings results on Monday, February 6th. The company reported $0.27 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.27. The business earned $483.70 million during the quarter, compared to analysts’ expectations of $474.07 million. Catalent’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.36 EPS. On average, equities analysts anticipate that Catalent Inc will post $1.38 EPS for the current fiscal year.
var userip;Your IP Address: document.write(userip);
Several hedge funds have recently added to or reduced their stakes in CTLT. Laurion Capital Management LP raised its stake in Catalent by 323.0% in the third quarter. Laurion Capital Management LP now owns 2,005,074 shares of the company’s stock worth $51,811,000 after buying an additional 1,531,074 shares during the last quarter. Arrowpoint Asset Management LLC raised its stake in shares of Catalent by 154.9% in the fourth quarter. Arrowpoint Asset Management LLC now owns 2,430,294 shares of the company’s stock valued at $65,521,000 after buying an additional 1,476,833 shares in the last quarter. Norges Bank purchased a new stake in shares of Catalent during the fourth quarter valued at about $36,835,000. BlackRock Fund Advisors raised its stake in shares of Catalent by 15.0% in the third quarter. BlackRock Fund Advisors now owns 6,579,877 shares of the company’s stock valued at $170,024,000 after buying an additional 858,781 shares in the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in shares of Catalent by 251.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,146,420 shares of the company’s stock valued at $30,908,000 after buying an additional 820,140 shares in the last quarter.
A number of research firms have issued reports on CTLT. TheStreet raised Catalent from a “d+” rating to a “c” rating in a research report on Monday, February 6th. Goldman Sachs Group Inc began coverage on Catalent in a research report on Thursday, December 1st. They set a “neutral” rating and a $25.00 price target for the company. Finally, Jefferies Group LLC boosted their price target on Catalent from $29.00 to $32.00 and gave the company a “hold” rating in a research report on Monday, February 27th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $28.71.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.